carbonthatcarbonthat
← Every company

Neurocrine Biosciences Inc Insider Trading

Every director, officer and 10% holder of Neurocrine Biosciences Inc has to report each trade in its stock within two business days of making it. This is those filings.

NBIX on carbonthat →
Insiders filing
12
56 reported lines
Open-market buys
0
Open-market sales
12
$7.9M
Net
$7.9M
sold more

Purchases and sales

Open-market trades only — the lines where someone chose to buy or sell at the going price.

InsiderActionValue
David W. BoyerChief Corp. Affairs Officer2026-09-14826 shat $157.45
Sale10b5-1 plan
$130.1K
Matt AbernethyChief Financial Officer2026-09-142.3K shat $157.20
Sale10b5-1 plan
$363.3K
Eric BenevichChief Commercial Officer2026-09-092.2K shat $154.61
Sale10b5-1 plan
$333K
Leslie V NorwalkDirector2026-07-281.3K shat $182.01
Sale10b5-1 plan
$227.5K
Ingrid DelaetChief Regulatory Officer2026-07-104.4K shat $181.02
Sale10b5-1 plan
$790.5K
Ingrid DelaetChief Regulatory Officer2026-07-098.4K shat $178.72
Sale10b5-1 plan
$1.5M
Darin LippoldtChief Legal Officer2026-07-0910K shat $179.60
Sale10b5-1 plan
$1.8M
Ingrid DelaetChief Regulatory Officer2026-07-082.7K shat $178.54
Sale10b5-1 plan
$488.7K
Ingrid DelaetChief Regulatory Officer2026-07-073.4K shat $178.57
Sale10b5-1 plan
$607.3K
Darin LippoldtChief Legal Officer2026-06-298.1K shat $170.03
Sale10b5-1 plan
$1.4M
Darin LippoldtChief Legal Officer2026-06-291.7K shat $170.81
Sale10b5-1 plan
$288.7K
Darin LippoldtChief Legal Officer2026-06-26200 shat $169.57
Sale10b5-1 plan
$33.9K

Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.

More on NBIX

Company overviewEverything on NBIX in one place, with the price.SEC filingsWhat NBIX's 8-Ks say happened: results, departures, auditor changes.Planned salesSales NBIX insiders have filed notice of.Executive payWhat NBIX awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in NBIX.Funds holding itWhich funds and ETFs hold NBIX, and how big a bet.LobbyingWhat NBIX spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on NBIX's account, and who they worked for.PatentsWhat NBIX is filing at the patent office.

Follow Neurocrine Biosciences Inc (NBIX) by email

New trades in Neurocrine Biosciences Inc (NBIX) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.

Unsubscribe with one click from any email.

Related datasets

PeopleCEOs, investors, public officials and market commentators.SEC FilingsAuditor changes, restatements, departures and results, from 8-Ks.Insider BuyingCluster buys, and chief executives buying their own stock.The InsidersOne page per filer: every company they file against.